Mustang Bio, Inc. (MBIO) Stock Price
MBIOStock
$0.55−66.59%52W
Market Cap$4.18M
P/E—
PEG Ratio—
Div yield—
Beta2.08
MBIO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-51.13%
Price vs S&P 500 (4W)-15.74%
VGM Score25.16
MBIO Earnings Surprise History
Q1 24-23.00est. -11.00
Q2 24-12.00est. -7.00
Q3 24-2.00est. -6.50
Q4 243.63est. -8.00
MBIO Analyst Recommendations
Sep 2024
Oct 2024
Nov 2024
Dec 2024
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MBIOMustang Bio, Inc. | — | — | D | $0.55 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Mustang Bio, Inc.
Mustang Bio is a clinical-stage biopharmaceutical company developing cell and gene therapies to treat hematologic cancers, solid tumors, and rare genetic diseases. The company's pipeline focuses on gene therapies for genetic disorders and CAR T cell therapies targeting hematologic malignancies and solid tumors.